EBR Systems has introduced the WiSE CRT System, an innovative leadless left ventricular pacing technology that received FDA approval in April 2025 and began U.S. commercialization targeting specialized patient segments. Despite technological differentiation and reimbursement progress, the company reports growing operating losses and substantial cash outflows typical of early-stage medtech commercialization. Regulatory post-approval commitments and capital constraints present significant challenges as EBR seeks to scale adoption domestically and expand internationally in select markets. Monitoring of clinical study enrollment, sales execution, and funding adequacy remains critical for near-term value realization.